Célia Jacoberger-Foissac
YOU?
Author Swipe
View article: NOD1 Agonist Induces Proliferation and Plasma Cell Differentiation of Mouse B Cells Especially CD23 <sup>high</sup> B Cells
NOD1 Agonist Induces Proliferation and Plasma Cell Differentiation of Mouse B Cells Especially CD23 <sup>high</sup> B Cells Open
Our results suggest that the NLR pathway could induce antibody development during infections and be exploited to develop more effective vaccination.
View article: Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma
Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma Open
Inhibition of adenosine A2A receptor (A2AR) is a promising approach for cancer immunotherapy currently evaluated in several clinical trials. We here report that anti-obesogenic and anti-inflammatory functions of A2AR, however, significantl…
View article: SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties Open
CD39 (ENTPD1) is a key enzyme responsible for degradation of extracellular ATP and is upregulated in the tumor microenvironment (TME). Extracellular ATP accumulates in the TME from tissue damage and immunogenic cell death, potentially init…
View article: Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function Open
Supplementary Figures 1-10 + Legends
View article: Data from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Data from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer Open
The ectonucleotidases CD39 and CD73 catalyze extracellular ATP to immunosuppressive adenosine, and as such, represent potential cancer targets. We investigated biological impacts of CD39 and CD73 in pancreatic ductal adenocarcinoma (PDAC) …
View article: Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function Open
Supplementary Figures 1-10 + Legends
View article: Data from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Data from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer Open
The ectonucleotidases CD39 and CD73 catalyze extracellular ATP to immunosuppressive adenosine, and as such, represent potential cancer targets. We investigated biological impacts of CD39 and CD73 in pancreatic ductal adenocarcinoma (PDAC) …
View article: Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function Open
Natural killer (NK) cell protection from tumor metastases is a critical feature of the host immune response to cancer, but various immunosuppression mechanisms limit NK cell effector function. The ectoenzyme, CD39, expressed on tumor-infil…
View article: Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function Open
Natural killer (NK) cell protection from tumor metastases is a critical feature of the host immune response to cancer, but various immunosuppression mechanisms limit NK cell effector function. The ectoenzyme, CD39, expressed on tumor-infil…
View article: Supplementary Tables and Figures from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Supplementary Tables and Figures from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer Open
supplementary Table S1 to S3; Supplementary Figure S1 to S9
View article: Supplementary Tables and Figures from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Supplementary Tables and Figures from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer Open
supplementary Table S1 to S3; Supplementary Figure S1 to S9
View article: Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity Open
We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP–P2-mediated proinflammatory responses. Using syngeneic and humanized tumor …
View article: Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity Open
We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP–P2-mediated proinflammatory responses. Using syngeneic and humanized tumor …
View article: Supplementary Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Supplementary Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity Open
Supplementary Methods, Figures, Legends and Tables
View article: Supplementary Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Supplementary Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity Open
Supplementary Methods, Figures, Legends and Tables
View article: CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer Open
The ectonucleotidases CD39 and CD73 catalyze extracellular ATP to immunosuppressive adenosine, and as such, represent potential cancer targets. We investigated biological impacts of CD39 and CD73 in pancreatic ductal adenocarcinoma (PDAC) …
View article: Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors Open
Neoadjuvant immunotherapy with anti-cytotoxic T lymphocyte–associated protein 4 (CTLA4) + anti–programmed cell death protein 1 (PD1) monoclonal antibodies has demonstrated remarkable pathological responses and relapse-free survival in ~80%…
View article: Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy Open
Background Concomitant tumor necrosis factor (TNF) neutralization in combination with immune checkpoint inhibitors (ICIs) reduces clinical immune-related adverse events (irAEs) and appears to improve antitumor efficacy in preclinical tumor…
View article: Liposomes as tunable platform to decipher the antitumor immune response triggered by TLR and NLR agonists
Liposomes as tunable platform to decipher the antitumor immune response triggered by TLR and NLR agonists Open
View article: Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity Open
We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP–P2-mediated proinflammatory responses. Using syngeneic and humanized tumor …
View article: Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform
Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform Open
View article: Développement de constructions liposomiques personnalisables pour une thérapie ciblée du cancer : la vaccination antitumorale
Développement de constructions liposomiques personnalisables pour une thérapie ciblée du cancer : la vaccination antitumorale Open
Currently, a challenging goal in the area of cancer treatment is the development of innovative targeted antitumoral immunotherapies with a long-term efficiency. In this context, we took advantage of liposomal nanoparticles properties for t…